This article reviews the primary circulatory liver diseases, which include Budd-Chiari syndrome, obstruction of the hepatic portion of the inferior vena cava, portal vein thrombosis, sinusoidal obstruction syndrome (veno-occlusive disease), nodular regenerative hyperplasia, and peliosis hepatis. In addition, two systemic cardiovascular diseases that impair hepatic circulation, ischemic hepatitis and congestive hepatopathy, are briefly discussed. A characteristic of the primary circulatory liver diseases is that portal hypertension usually precedes liver dysfunction; however, this is not the case with the primary parenchymal liver diseases, in which liver dysfunction always progresses before portal hypertension is manifested. Significant overlap exists among the diseases and risk factors that predispose patients to the primary circulatory liver diseases, though the pathogenesis of individual diseases varies.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
References and Recommended Reading
Okuda K, Kage M, Shrestha SM: Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology 1998, 28:1191–1198.
Denninger MH, Chait Y, Casadevall N, et al.: Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000, 31:587–591. One of two pivotal studies characterizing the prothrombotic risk factors for BCS and portal vein thrombosis.
Janssen HL, Meinardi JR, Vleggaar FP, et al.: Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000, 96:2364–2368. A second important study characterizing the prothrombotic risk factors for BCS and portal vein thrombosis.
Rosenberg RD, Aird WC: Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999, 340:1555–1564. The authors discuss the novel concept that endothelial cell heterogeneity is responsible for determining why systemic hypercoagulable states target specific vascular beds rather than causing thrombosis in random locations.
Ryu RK, Durham JD, Krysl J, et al.: Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. J Vasc Interv Radiol 1999, 10:799–805.
Ganger DR, Klapman JB, McDonald V, et al.: Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis. Am J Gastroenterol 1999, 94:603–608.
Campbell DA, Jr., Rolles K, Jamieson N, et al.: Hepatic transplantation with perioperative and long term anticoagulation as treatment for Budd-Chiari syndrome. Surg Gynecol Obstet 1988, 166:511–518.
Slakey DP, Klein AS, Venbrux AC, et al.: Budd-Chiari syndrome: current management options. Ann Surg 2001, 233:522–527.
Tefferi A, Solberg LA, Silverstein MN: A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 2000, 109:141–149. Primary myeloproliferative disorders predispose to BCS, portal vein thrombosis, NRH, and peliosis hepatis. This review of two of the three chronic myeloproliferative disorders provides valuable information on clinical management.
Cortelazzo S, Finazzi G, Ruggeri M, et al.: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995, 332:1132–1136.
Valla D, Condat B: Portal vein thrombosis in adults: pathophysiology, pathogenesis, and management. J Hepatol 2000, 32:865–871.
Condat B, Pesslore F, Hillaire S, et al.: Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001, 120:490–497.
Bras G, Jeliffe DB, Stuart KL: Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica. Arch Pathol 1954, 57:285–300.
Shulman HM, Fisher LB, Schoch HG, et al.: Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994, 19:1171–1181.
DeLeve LD, McCuskey RS, Wang X, et al.: Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999, 29:1779–1781.
DeLeve LD, Shulman HM, McDonald GB: Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venoocclusive disease). Semin Liver Dis 2002, 22:27–42. This review article was cowritten by a basic investigator, a pathologist, and a clinical investigator. The range in expertise of the authors permits a comprehensive discussion of sinusoidal obstruction syndrome.
DeLeve LD: Dacarbazine toxicity in murine liver cells: a novel model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994, 268:1261–1270.
DeLeve LD, Wang X, Kuhlenkamp JF, et al.: Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venooclusive disease. Hepatology 1996, 23:589–599.
DeLeve LD: Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996, 24:830–837.
Shulman HM, McDonald GB, Matthews D, et al.: An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980, 79:1178–1191.
McDonald GB, Hinds MS, Fisher LD, et al.: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993, 118:255–267.
Rollins BJ: Hepatic veno-occlusive disease. Am J Med 1986, 81:297–306
Jones RJ, Lee KSK, Beschorner WE, et al.: Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987, 44:778–783.
Lee JL, Gooley T, Bensinger W, et al.: Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transpl 1999, 5:306–315.
M’eresse V, Hartmann O, Vassal G, et al.: Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transpl 1992, 10:135–141.
McCune JS, Gibbs JP, Slattery JT: Plasma concentration monitoring of busulfan: Does it improve clinical outcome? Clin Pharmacokinet 2000, 39:155–165.
Bearman SI, Lee JL, Bar’on AE, et al.: Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997, 89:1501–1506.
Azoulay D, Castaing D, Lemoine A, et al.: Successful treatment of severe azathioprine-induced hepatic veno-occlusive disease in a kidney-transplanted patient with transjugular intrahepatic portosystemic shunt. Clin Nephrol 1998, 50:118–122.
Kulkarni S, Rodriguez M, Lafuente A, et al.: Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transpl 1999, 23:803–807.
Azoulay D, Castaing D, Lemoine A, et al.: Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transpl 2000, 25:987–992.
Rajvanshi P, McDonald GB. Expanding the use of transjugular intrahepatic portosystemic shunts for veno-occlusive disease. Liver Transplant 2001; 7:154.
Zenz T, Rössle M, Bertz H, et al.: Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation-role of transjugular intrahepatic portosystemic shunt (TIPS). Liver 2001, 21:31–36.
Carreras E, Bertz H, Arcese W, et al.: Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998, 92:3599–3604.
Ganem G, Saint-Marc Girardin MF, Kuentz M, et al.: Venocclusive disease of the liver after allogeneic bone marrow transplantation in man. Int J Radiat Biol Phys 1988, 14:879–884.
McDonald GB, Sharma P, Matthews DE, et al.: The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985, 36:603–608.
Bearman SI: The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995, 85:3005–3020.
Wanless IR: Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990, 11:787–797.
Nakanuma Y: Nodular regenerative hyperplasia of the liver: retrospective survey in autopsy series. J Clin Gastroenterol 1990, 12:460–465.
Wanless IR, Godwin TA, Allen F, et al.: Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine 1980, 59:367–379.
Shimamatsu K, Wanless IR: Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology 1997, 26:343–350.
Haboubi NY, Ali HH, Whitwell HL, et al.: Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 1988, 83:256–261.
Snover DC, Weisdorf S, Bloomer J, et al.: Nodular regenerative hyperplasia of the liver following bone marrow transplantation. Hepatology 1989, 9:443–448.
Leong SS, Cazen RA, Yu GS, et al.: Abdominal visceral peliosis associated with bacillary angiomatosis: ultrastructural evidence of endothelial destruction by bacilli. Arch Pathol Lab Med 1992, 116:866–871.
Scoazec JY, Marche C, Girard PM, et al.: Peliosis hepatis and sinusoidal dilation during infection by the human immunodeficiency virus (HIV): an ultrastructural study. Am J Pathol 1988, 131:38–47.
Goerdt S, Sorg C: Endothelial heterogeneity and the acquired immunodeficiency syndrome: a paradigm for the pathogenesis of vascular disorders. Clin Invest 1992, 70:89–98.
DeLeve LD: Glutathione defense in non-parenchymal cells. Semin Liver Dis 1998, 18:403–413.
Zafrani ES, Cazier A, Baudelot AM, et al.: Ultrastructural lesions of the liver in human peliosis: a report of 12 cases. Am J Pathol 1984, 114:349–358.
DeLeve LD: Cancer chemotherapy. In Drug-induced Liver Disease.Edited by Kaplowitz N, DeLeve LD. New York: Marcel Dekker;2002:593–632.
Seeto RK, Fenn B, Rockey DC: Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000, 109:109–113.
McDonald GB, Sharma P, Matthews DE, et al.: Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis,incidence and predisposing factors. Hepatology 1984, 4:116–122.
About this article
Cite this article
DeLeve, L.D. Vascular liver diseases. Curr Gastroenterol Rep 5, 63–70 (2003). https://doi.org/10.1007/s11894-003-0011-0
- Inferior Vena Cava
- Transjugular Intrahepatic Portosystemic Shunt
- Portal Vein Thrombosis
- Polycythemia Vera
- Essential Thrombocythemia